• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    TFF Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

    8/11/22 4:05:00 PM ET
    $TFFP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TFFP alert in real time by email

    Phase 2 Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder Programs Continue to Advance

    Expands R&D Operations with New Austin, TX Facility

    Recent Feasibility Work Confirms Utility of Thin Film Freezing in Developing Next- Generation Vaccines

    Conference Call and Webcast Scheduled Today, Thursday, August 11, 2022, at 4:30 PM ET

    FORT WORTH, Texas, Aug. 11, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today reported financial results for the second quarter of 2022 and provided an update on recent corporate and clinical developments. The Company will discuss the highlights on a conference call and webcast, scheduled for today, Thursday, August 11, 2022, at 4:30 PM ET.

    "We enter the second half of 2022 with significant momentum based upon the continued advancement of our internal pipeline coupled with growing recognition that our Thin Film Freezing technology has the potential to revolutionize drug delivery across a diverse array of molecules," said Glenn Mattes, CEO of TFF Pharmaceuticals. "We have initiated Phase 2 studies for our two lead internal product candidates, Inhaled Voriconazole Powder (TFF VORI) and Inhaled Tacrolimus Powder (TFF TAC), and we are engaged in active outreach with a number of companies that have expressed interest in these two innovative programs. Importantly, the VORI and TAC programs also serve to further validate the clinical utility of Thin Film Freezing technology, sending a clear signal to the industry that applications of our technology continue to grow and advance further into human testing.

    "Our partnering activity also remains robust, and we are now working with three additional top 20 pharma companies. With more than 20 disclosed collaborations and well over 50 material transfer agreements, we continue to make significant progress

    with our industry and academic partners, consistently demonstrating how Thin Film Freezing offers a unique and versatile solution for significantly improving formulations for safer, more targeted drug delivery. We expect many of these programs to advance further into preclinical and clinical testing later this year. As the success of our partnerships continues to grow, we also anticipate that many of our existing partners will expand their relationship with TFF as well as open up the opportunity for developing new relationships.

    "To accommodate current and future demand for Thin Film Freezing partnerships, in July we announced the opening of a new R&D facility located in Austin, Texas that provides us with significantly more laboratory space. This 3,500 square feet facility includes a dedicated lab for downstream processing of preclinical products created via Thin Film Freezing, which will complement the company's existing formulation development capabilities. As TFF expands its in-house and partnered research, including applications in biologics, the Austin facility will also allow us to accommodate larger equipment to facilitate scale-up and manufacturing for preclinical studies.

    "A major reason for our R&D expansion also relates to the increased feasibility work surrounding our next-generation vaccine programs. There is a growing body of scientific evidence suggesting that, when compared to conventional delivery, mucosal-based delivery of vaccines may reduce the burden of infectious diseases by providing first-line protection at viral entry points.1 We have successfully completed multiple feasibility studies with Thin Film Freezing demonstrating how our unique, dry powder-based formulations can be successfully delivered to both lung and nasal regions to elicit a robust host immune response. As this area of work continues to grow, we look forward to providing additional updates on our vaccine applications later this year.

    "We have recently delivered the final published clinical study report for Inhaled Niclosamide Powder to our partner, UNION Therapeutics. Union is working diligently to provide TFF with feedback on their option to license Niclosamide Inhalation Powder. We continue to believe that the widespread availability of potent antiviral medicines is key to significantly lowering mortality and morbidity associated with COVID-19 infection.

    "We believe the second half of the year is shaping up to be a very exciting period for TFF Pharmaceuticals. As a reminder, we spent the first half of 2022 positioning the company for significant growth by advancing our two lead pipeline assets into Phase 2 testing, forging important new strategic alliances, expanding the applications of our technology platform across a wide spectrum of molecules, and making key senior level appointments to help drive our growth while optimizing our capital and operational efficiencies. We look forward to announcing additional progress throughout the remainder of 2022."

    Conference Call and Webcast Information

    The Company will host a conference call today, Thursday, August 11, 2022, at 4:30 PM, Eastern Time, to review the clinical, corporate and financial highlights. To participate in the conference call, please dial the following numbers prior to the start of the call:

     Domestic Dial-In Number: Toll-Free: 1-855-327-6837 
       
     International Dial-In Number: 1-631-891-4304 
       
     Conference ID: 10019661 
       

    The call will also be broadcast live over the Web and can be accessed on TFF Pharmaceuticals' Website, https://tffpharma.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47

    Please access the Company's website at least 15 minutes ahead of the conference to register, download, and install any necessary audio software. The conference call will also be available for replay for one month on the Company's website in the Events Calendar of the Investors section.

    Recent Clinical and Corporate Highlights:

    • In July, the Company announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin, Texas. The new facility of over 3,500 square feet significantly increases TFF's total lab space, adding a dedicated lab for downstream processing of products created via Thin Film Freezing, which will complement the company's existing formulation development capabilities. The new space will be supervised by Donald Owens, Ph.D., Director of Product Development at TFF, and supported by John Koleng, Ph.D., R.Ph., Vice President of Product Development and Manufacturing. The company also plans to expand the product development team in Austin, which will be based at the new facility, to support the growing number of partnered projects.

    Strategic Business Development and Partnership Activities – Biopharmaceutical Companies and Research Institutions:

    • In July, Dr. Bill Williams, co-inventor of the Thin Film Freezing technology, published an editorial review article in Biopharm International entitled, "Improved Formulations to Enable Stable Delivery of Biologics". The article highlights the significant advantages of Thin Film Freezing over conventional freeze-drying processes, including improvements with respect to less particle aggregation and less protein denaturation, which can overcome challenges in the formulation and delivery of biologics.
    • In May, the Company announced multiple presentations highlighting the broad applicability of its Thin Film Freezing Technology at the Respiratory Drug Delivery Meeting (RDD). Dr. Williams delivered a platform presentation with data on stabilizing and delivering antivirals, antibodies and vaccines using Thin Film Freezing technology in the fight against COVID-19 and other serious viral infections. Additionally, Dr. Williams and his colleagues presented five posters highlighting the broad applicability of Thin Film Freezing to improve drug development of biologics and small molecules for respiratory diseases, including pulmonary fibrosis and COVID-19. The findings from Dr. Williams' lab also highlighted how Thin Film Freezing can be used to facilitate delivery of other treatment modalities, such as gene therapy.

    • In April, the Company announced safety and pharmacokinetic data from its Phase 1 study of Niclosamide Inhalation Powder, which is being developed as a potential treatment for COVID-19. The data showed that Niclosamide Inhalation Powder was well tolerated with no serious adverse events across all subject cohorts. TFF Pharmaceuticals believes the 6 mg dose level of Niclosamide Inhalation Powder is estimated to produce a concentration of >100 μM in the epithelial lining fluid in the lung following delivery as a dry powder, which would be considered highly potent with respect to inhibiting viral replication. A single administration of 6 mg of Niclosamide Inhalation Powder to the lungs provided equal mean maximum drug concentration (Cmax) in the blood as 100 mg delivered as a nebulized spray to the lungs and nasal cavity, as demonstrated in a recent publication.2

    Financial Results

    For the quarter ended June 30, 2022, compared to quarter ended June 30, 2021

    • Cash Position: As of June 30, 2022, TFF Pharmaceuticals reported cash and cash equivalents of $20.9 million.

    • Research and Development (R&D) expenses: R&D expenses for the second quarter of 2022 were $5.1 million, compared to $2.8 million in 2021.
    • General & Administrative (G&A) expenses: G&A expenses for the second quarter of 2022 were $3.7 million, compared to $2.4 million in 2021.
    • Net Loss: TFF Pharmaceuticals reported a net loss for the second quarter of 2022 of $8.7 million, compared to a net loss of $4.7 million in 2021.

    ABOUT TFF PHARMACEUTICALS' THIN FILM FREEZING TECHNOLOGY PLATFORM

    TFF Pharmaceuticals' proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The Thin Film Freezing process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by Thin Film Freezing can deliver as much as 75% of the dose to the deep lung. Thin Film Freezing does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of Thin Film Freezing can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products.

    ABOUT TFF PHARMACEUTICALS

    TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety and stability. The company's versatile Thin Film Freezing (TFF) technology platform has broad applicability to convert any drug, including vaccines, small and large molecules and biologics, into an elegant dry powder highly advantageous for inhalation, with improved absorption so drugs can also be delivered to the eyes, nose and topically to the skin. TFF has two lead drug candidates in the clinic: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder, and continues to expand its pipeline by collaborating with a broad array of pharmaceutical companies, academic institutions and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the U.S. and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company's website at https://tffpharma.com.

    SAFE HARBOR

    This press release contains forward-looking statements regarding TFF Pharmaceuticals, Inc., including the expectations for its continued development of Inhaled Tacrolimus and

    Voriconazole Powders, the benefits of the Company's TFF platform and the Company's plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of its Inhaled Tacrolimus, Voriconazole Powders or any of its dry powder product candidates, (ii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iii) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (iv) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (v) those other risks disclosed in the section "Risk Factors" included in the Company's 2021 Annual Report on Form 10-K filed with the SEC on March 24, 2022. TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements. TFF Pharmaceuticals does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

    1 https://pubmed.ncbi.nlm.nih.gov/31669546/

    2 https://www.sciencedirect.com/science/article/pii/S2666776221000612?via%3Dihub

    Investor Relations Contact:

    Corey Davis, Ph.D. LifeSci Advisors

    212-915-2577

    [email protected] 

    Media Contact:

    Gwendolyn Schanker LifeSci Communications

    (269) 921-3607

    [email protected]



    TFF PHARMACEUTICALS, INC.
    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
     
      Three Months  Three Months  Six Months  Six Months 
    EndedEndedEndedEnded
    June 30,June 30,June 30,June 30,
    2022202120222021
    Grant revenue $28,004  $1,850  $95,439  $26,165 
    Operating expenses:                
    Research and development  5,110,805   2,762,170   10,372,409   8,040,422 
    General and administrative  3,690,010   2,351,007   6,936,205   4,998,422 
    Total operating expenses  8,800,815   5,113,177   17,308,614   13,038,844 
                     
    Loss from operations  (8,772,811)  (5,111,327)  (17,213,175)  (13,012,679)
                     
    Other income:                
    Other income  20,606   441,546   77,783   672,824 
    Interest income  5,880   14,069   13,065   29,568 
    Total other income  26,486   455,615   90,848   702,392 
                     
    Net loss $(8,746,325) $(4,655,712) $(17,122,327) $(12,310,287)
                     
    Net loss per share, basic and diluted $(0.34) $(0.18) $(0.67) $(0.51)
    Weighted average common shares  25,373,706   25,369,144   25,372,749   24,261,032 
    outstanding, basic and diluted
                     



    TFF PHARMACEUTICALS, INC.
    CONDENSED CONSOLIDATED BALANCE SHEETS
      June 30,  December 31, 
    20222021
       (Unaudited)     
    ASSETS        
    Current assets:        
    Cash and cash equivalents $20,890,253  $33,794,672 
    Receivable due from collaboration agreement  1,812,975   1,628,703 
    Research and development tax incentive receivable  994,549   966,646 
    Prepaid assets and other current assets  1,483,953   2,447,930 
    Total current assets  25,181,730   38,837,951 
    Operating lease right-of-use asset, net  232,138   - 
    Property and equipment, net  2,332,254   1,859,860 
    Other assets  167,077   - 
    Total assets $27,913,199  $40,697,811 
             
    LIABILITIES AND STOCKHOLDERS' EQUITY        
             
    Current liabilities:        
    Accounts payable $3,480,461  $1,493,842 
    Accrued compensation  -   416,910 
    Deferred research grant revenue  268,000   50,000 
    Current portion of operating lease liability  79,050   - 
    Total current liabilities  3,827,511   1,960,752 
    Operating lease liability, net of current portion  146,188   - 
    Total liabilities  3,973,699   1,960,752 
             
    Commitments and contingencies        
             
    Stockholders' equity:        
    Common stock  25,374   25,372 
    Additional paid-in capital  106,461,934   104,078,968 
    Accumulated other comprehensive loss  (107,121)  (48,921)
    Accumulated deficit  (82,440,687)  (65,318,360)
    Total stockholders' equity  23,939,500   38,737,059 
    Total liabilities and stockholders' equity $27,913,199  $40,697,811 



    Primary Logo

    Get the next $TFFP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TFFP

    DatePrice TargetRatingAnalyst
    5/19/2022$22.00Buy
    H.C. Wainwright
    More analyst ratings

    $TFFP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by TFF Pharmaceuticals Inc.

      SC 13G/A - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

      11/19/24 4:05:58 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by TFF Pharmaceuticals Inc.

      SC 13G - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

      11/14/24 3:37:45 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by TFF Pharmaceuticals Inc.

      SC 13G - TFF Pharmaceuticals, Inc. (0001733413) (Subject)

      5/8/24 5:13:05 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TFFP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Weisman Harlan F was granted 27,480 shares, increasing direct ownership by 3% to 842,095 units (SEC Form 4)

      4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)

      7/8/24 5:46:27 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Catherine Chai-Zon was granted 1,583 shares (SEC Form 4)

      4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)

      7/8/24 5:44:38 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Mills Robert S was granted 3,165 shares, increasing direct ownership by 6% to 59,145 units (SEC Form 4)

      4 - TFF Pharmaceuticals, Inc. (0001733413) (Issuer)

      7/8/24 5:44:15 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TFFP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on TFF Pharmaceuticals with a new price target

      H.C. Wainwright resumed coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $22.00

      5/19/22 9:05:50 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright reiterated coverage on TFF Pharmaceuticals with a new price target

      HC Wainwright reiterated coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $37.00 from $31.00 previously

      3/11/21 8:08:25 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on TFF Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of TFF Pharmaceuticals with a rating of Buy and set a new price target of $37.00 from $31.00 previously

      3/5/21 6:29:56 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TFFP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • TFF Pharmaceuticals Announces Delisting from Nasdaq and Potential SEC Deregistration

      FOXBOROUGH, Mass., Feb. 6, 2025 /PRNewswire/ -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has provided notification to The Nasdaq Stock Market, LLC ("Nasdaq") of its intent to voluntarily delist the Company's common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. The Company expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of its Common Stock on or about February 16, 2025. The removal of the Common Stock from Nasdaq will be effective 10 days after the filing of the Form 25. The Company has made no arrangements for

      2/6/25 4:05:00 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Announces It Will Wind Down Operations

      FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, Chief Financial Officer, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of office

      11/14/24 4:15:00 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug Delivery

      FORT WORTH, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (NASDAQ:TFFP) (the "Company" or "TFF Pharmaceuticals"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, announces positive preclinical data published in the Journal of Drug Delivery Science and Technology further validating the Company's TFF technology as superior approach to formulate dry powders for pulmonary drug delivery. The study demonstrates the superiority of TFF inhalational dry powders over jet-milling and spray-drying technologies in a rat model, with enhanced uniform drug

      9/26/24 7:00:00 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TFFP
    Leadership Updates

    Live Leadership Updates

    See more
    • TFF Pharmaceuticals Announces It Will Wind Down Operations

      FORT WORTH, Texas, Nov. 14, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) today announced that the Company has terminated its employees and will wind down its operations. This decision was made at a special meeting of the board of directors. The board of directors appointed Craig R. Jalbert, age 63, as the Company's CEO, President, Chief Financial Officer, Treasurer and Secretary, and sole member of the board. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of office

      11/14/24 4:15:00 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors

      FORT WORTH, Texas, Dec. 13, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Thomas B. King to its Board of Directors. "I am pleased to welcome Thomas King to our Board of Directors," said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. "Tom is an exceptionally accomplished executive who has held leadership positions at life sciences companies over the last three decades. In addition, his extensive board experience will p

      12/13/23 8:00:00 AM ET
      $ACHV
      $TFFP
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors

      FORT WORTH, Texas, Nov. 30, 2023 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced the appointment of Michael Patane, Ph.D., to its Board of Directors. "I am pleased to welcome Dr. Patane to our Board of Directors," said Harlan Weisman, M.D., Vice Chairman and Chief Executive Officer of TFF Pharmaceuticals. "Mike's career spans over two decades of leadership experience in drug discovery and development, and he has demonstrated an extraordinary ability to turn scientific success into corp

      11/30/23 8:00:00 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TFFP
    Financials

    Live finance-specific insights

    See more
    • TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

      Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to Demonstrate Antifungal Activity and a Favorable Safety and Tolerability Profile TFF TAC Program Prioritized Based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and Substantial Market Opportunity Company to Hold Conference Call and Webcast Today at 4:30 pm ET FORT WORTH, Texas , March 27, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing

      3/27/24 4:01:00 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Announces Update on Clinical Programs

      Company to Prioritize Clinical Development of Tacrolimus Inhalation Powder (TFF TAC) based on Positive Phase 2 Data, the Potential to Address a Significant Unmet Need in Lung Transplant Medicine and Substantial Market Opportunity Company to Evaluate Strategic Options for TFF VORI, including Partnerships, Collaborations, and Grants following Positive Data from Phase 2 Study and the Expanded Access Program (EAP) Company to Discuss Clinical Updates on TFF TAC and TFF VORI on Wednesday, March 27, 2024 at 4:30 pm ET FORT WORTH, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) ("the Company"), a clinical-stage biopharmaceutical company focused on developing an

      3/20/24 9:03:36 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TAC

      Treatment with TFF VORI resulted in positive treatment outcomes based on clinical, mycologic and radiologic responses while maintaining a favorable safety/tolerability profile, with no all-cause mortality, no invasive pulmonary aspergillosis (IPA)-related mortality, and no TFF VORI discontinuations due to an adverse event (AE) Successful transition of all four patients from oral tacrolimus to TFF TAC, leading to significant lowering of tacrolimus blood levels with no clinical evidence of acute rejection; all patients who completed Part A (study treatment period) of the trial chose to remain on TFF TAC and advance to Part B (extension study) TFF TAC was well tolerated, with no mortality a

      12/19/23 6:00:00 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TFFP
    SEC Filings

    See more
    • SEC Form DEF 14A filed by TFF Pharmaceuticals Inc.

      DEF 14A - TFF Pharmaceuticals, Inc. (0001733413) (Filer)

      12/23/24 6:50:03 AM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by TFF Pharmaceuticals Inc.

      PRE 14A - TFF Pharmaceuticals, Inc. (0001733413) (Filer)

      12/11/24 4:05:37 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TFF Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - TFF Pharmaceuticals, Inc. (0001733413) (Filer)

      12/10/24 4:05:34 PM ET
      $TFFP
      Biotechnology: Pharmaceutical Preparations
      Health Care